Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 8/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357025 | 0.93 | PIK3CG (0.87) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL4556978 | 0.92 | PIK3CG (0.85) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL4595806 | 0.86 | PIK3CG (0.76) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL4344758 | 0.86 | PIK3CG (0.75) | PIK3CGFYNTGFBR2BRAF | |
| SCHEMBL4325681 | 0.86 | PIK3CG (0.75) | PIK3CGFYNTGFBR2BRAF | |
| SCHEMBL4341278 | 0.85 | PIK3CG (0.75) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL4340607 | 0.85 | PIK3CG (0.73) | PIK3CGFYNTGFBR2BRAF | |
| SCHEMBL4594025 | 0.84 | PIK3CG (0.72) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL14302657 | 0.84 | FYN (0.76) | PIK3CGFYNRETTGFBR2BRAF | |
| SCHEMBL4335832 | 0.84 | PIK3CG (0.72) | PIK3CGFYNRETPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | claimed |
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | PIK3CG 756/4885FYN 151/4885RET 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.